S-nitrosylation is a ubiquitous protein modification emerging as a principal mechanism of nitric oxide (NO)-mediated signal transduction and cell function. S-nitrosylases can use NO synthase (NOS)-derived NO to modify selected cysteines in target proteins. Despite proteomic identification of over a thousand S-nitrosylated proteins, few S-nitrosylases have been identified. Moreover, mechanisms underlying site-selective S-nitrosylation and the potential role of specific sequence motifs remain largely unknown. Here, we describe a stimulus-inducible, heterotrimeric S-nitrosylase complex consisting of inducible NOS (iNOS), S100A8, and S100A9. S100A9 exhibits transnitrosylase activity, shuttling NO from iNOS to the target protein, whereas S100A8 and S100A9 coordinately direct site selection. A family of proteins S-nitrosylated by iNOS-S100A8/A9 were revealed by proteomic analysis. A conserved I/L-X-C-X 2 -D/E motif was necessary and sufficient for iNOS-S100A8/ A9-mediated S-nitrosylation. These results reveal an elusive parallel between protein S-nitrosylation and phosphorylation, namely, stimulus-dependent posttranslational modification of selected targets by primary sequence motif recognition.
INTRODUCTION
Protein S-nitrosylation is a nitric oxide (NO)-dependent posttranslational modification of cysteine that regulates protein structure and function in bacteria, plants, and mammals Seth et al., 2012; Yun et al., 2011 ). An activated NO moiety is covalently added to the free thiol group on cysteine, generating an S-nitrosothiol. High-throughput proteomic approaches have identified more than a thousand S-nitrosylated (SNO-) proteins and linked to diverse cellular functions (Doulias et al., 2010; Seth and Stamler, 2011) . Physiological S-nitrosylation contributes to cellular homeostasis, whereas, dysregulation can lead to severe pathological consequences (Haldar and Stamler, 2013; Lim et al., 2008a; .
Like phosphorylation and ubiquitination, protein S-nitrosylation is regulatable, reversible, and target and site selective. However, the mechanism underlying selectivity has remained elusive. The eukaryotic nitric oxide synthase (NOS) family has three cell-selective isoforms, neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS). There is limited evidence that NOS can mediate selective S-nitrosylation via direct NOS-substrate interactions (Fang et al., 2000; García-Cardeñ a et al., 1998; Kim et al., 2005) ; however, this mechanism is unlikely to account for selective targeting of Cys residues in a multitude of distinct protein substrates by only three NOS isoforms. An alternative adaptor mechanism is supported by reports that certain SNO-proteins have S-nitrosylase activity and can transfer NO from its own S-nitrosothiol group to a free thiol on a target protein via direct protein-protein interaction. Fewer than ten S-nitrosylases have been identified to date , and the primary sequences and structures that establish the rules governing specificity of substrate recognition and cysteine transnitrosylation are largely unknown. Recent global analyses of S-nitrosocysteine sites revealed information on specific determinants of S-nitrosylation, but failed to identify a primary sequence motif for site-selective S-nitrosylation (Doulias et al., 2010; Hao et al., 2006; Marino and Gladyshev, 2010) . Together, these findings suggest that additional S-nitrosylases, mechanisms, and motifs are yet to be revealed.
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is a key glycolytic enzyme and a well-studied S-nitrosylation target. S-nitrosylation of GAPDH regulates enzymatic activity (Padgett and Whorton, 1995) , but also mediates several ''moonlighting'' functions (Jia et al., 2012; Kornberg et al., 2010) . Recently, we reported that selective, inducible S-nitrosylation of GAPDH dysregulates translational control of gene expression by the interferon-gamma (IFN-g)-activated inhibitor of translation (GAIT) complex (Jia et al., 2012) . GAPDH, along with ribosomal protein L13a, Glu-Pro tRNA synthetase (EPRS), and NS1-associated protein are induced by IFN-g to form the GAIT complex (Sampath et al., 2004 ) that inhibits translation of vascular endothelial growth factor-A (VEGF-A) and other inflammation-related mRNAs (Ray et al., 2009; Vyas et al., 2009 ). Low-density lipoprotein (LDL) that is oxidatively-modified (LDL ox ) by the physiological myeloperoxidase (MPO) system suppresses GAIT system activity by selective S-nitrosylation of GAPDH Cys 247 , a residue distant from the catalytic domain. S-nitrosylated GAPDH fails to bind and protect L13a, leading to ubiquitination and proteasomal degradation of L13a and consequent GAIT system inactivation. Here, we elucidate the molecular mechanism underlying stimulus-dependent, site-selective S-nitrosylation of GAPDH, revealing an inducible heterotrimeric S-nitrosylase complex and a consensus motif that directs specific S-nitrosylation on multiple target proteins.
RESULTS iNOS Is Required for LDL ox /IFN-g-Inducible S-Nitrosylation of GAPDH Cys 247
To determine the role of enzymatically generated NO in GAPDH S-nitrosylation, NOS inhibitors were used. Human peripheral blood monocytes (PBM) were transfected with HAtagged GAPDH (HA-GAPDH) plasmids bearing Cys-to-Ser mutations at each of the three Cys residues, or wild-type. Cells were then incubated with IFN-g and LDL ox for 24 hr in the presence of the nonselective NOS inhibitor, L-NMMA (NG-monomethyl-L-arginine acetate). The biotin-switch assay revealed specific S-nitrosylation of GAPDH at Cys 247 and suppression by L-NMMA ( Figure 1A ). Also, GAPDH S-nitrosylation was completely suppressed by 1400W ( Figure 1B ), which exhibits a 1,000-fold selectivity for iNOS, the principal myeloid cell isoform (Garvey et al., 1997; Hara et al., 2005) . IFN-g and LDL ox markedly induced iNOS mRNA and protein in PBM; however, the individual agonists were only modestly stimulatory ( Figure 1C ). iNOS-specific siRNA blocked iNOS induction and GAPDH S-nitrosylation supporting its critical role ( Figure 1D ). Figure 1E ). To determine the specific role of LDL ox in the iNOS-GAPDH interaction, U937 cells were transfected with His-tagged iNOS and then treated with LDL ox for 24 hr in absence of IFN-g. LDL ox by itself was sufficient to induce protein interaction, thus revealing a dual function of LDL ox in both iNOS induction and interaction with GAPDH (Figure 1F ). To determine whether iNOS by itself is sufficient for GAPDH S-nitrosylation, cells were transfected with His-iNOS but S-nitrosylation was not observed in the absence of LDL ox / IFN-g, indicating iNOS is necessary but not sufficient for modification ( Figure 1G ).
Dysregulation of GAIT System by LDL ox /IFN-g Requires iNOS
To establish the role of iNOS in GAPDH S-nitrosylation and L13a degradation, bone marrow-derived macrophages (BMDM) isolated from iNOS À/À and wild-type mice were incubated with IFN-g or LDL ox or both. LDL ox /IFN-g-inducible S-nitrosylation of GAPDH was observed in BMDM from wild-type but not iN-OS À/À mice ( Figure 1H ). Likewise, GAPDH-L13a interaction was not inhibited by LDL ox /IFN-g in iNOS À/À BMDM, subsequently preventing L13a degradation. Finally, we investigated the role of iNOS À/À in GAIT system inactivation by LDL ox /IFN-g that prevents delayed translational silencing of GAIT elementbearing target mRNAs, e.g., VEGF-A and ceruloplasmin (Cp), thereby prolonging their expression (Jia et al., 2012) . Synthesis of VEGF-A and Cp in agonist-treated BMDM was determined by 35 S-Met metabolic labeling. BMDM from wild-type mice exhibited translational silencing after 24 hr of IFN-g treatment that was prevented by LDL ox ( Figure 1I ). Likewise, expression of GAIT targets was silenced by IFN-g in BMDM from iNOS À/À mice. However, LDL ox failed to prevent the inhibition, consistent with a critical role of iNOS-driven S-nitrosylation of GAPDH in regulating GAIT system activity.
S100A8/9 Complex Mediates Binding of iNOS to GAPDH
Human GAPDH is a multifunctional protein containing Cys residues at 152, 156, and 247. LPS-stimulated S-nitrosylation of GAPDH Cys 152 contributes to its role in apoptotic signaling and heme trafficking (Chakravarti et al., 2010; Hara et al., 2005) , whereas LDL ox /IFN-g-stimulated S-nitrosylation of Cys 247 prevents GAIT system activation (Jia et al., 2012) . Like Cys 247 S-nitrosylation, iNOS is essential for Cys 152 S-nitrosylation as well (Hara et al., 2005) . However, in neither case is the mechanism of selective S-nitrosylation known. Differential nitrosylation of distinct sites by iNOS suggests potential recruitment of other proteins to provide site selectivity. To identify interacting proteins, lysates from LDL ox /IFN-g-treated PBM were immunoprecipitated with anti-iNOS or anti-GAPDH antibody and resolved by electrophoresis and silver stain ( Figure 2A ). Proteins in enriched bands were identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) (Table S1 available online). Two proteins, histone H2A and S100A9, were captured by both antibodies. However, immunoblot analysis failed to show an interaction between H2A and iNOS or GAPDH ( Figure S1 ). S100A9 is an inflammatory mediator that forms a heterodimeric complex with S100A8 in myeloid cells (Roth et al., 2003) . Notably, S100A8 was also detected by LC-MS (Table S1 ). Detection of iNOS and GAPDH, as positive controls, validated the approach. LDL ox /IFN-g did not induce expression of S100A8 or S100A9 ( Figure 2B ), but led to the inducible assembly of a complex containing all four proteins ( Figure 2C ). In the absence of stimulation, only S100A8 and S100A9 were found to interact. We used a knockdown approach to determine whether S100A8 and S100A9 are necessary for interaction of the NO donor, iNOS, with its target, GAPDH. Depletion of GAPDH did not disrupt iNOS binding to S100A8/A9, and S100A8 depletion did not block the interaction of the other three components ( Figure 2D , left). However, S100A9 depletion prevented the binding of iNOS to GAPDH and S100A8, suggesting S100A9 is an indispensable intermediary for iNOS interaction with its S-nitrosylation target, GAPDH ( Figure 2D , right). To determine the specific stimulus-dependence of iNOS binding to S100A8/A9, PBM were transfected with His-iNOS. LDL ox by itself, but not IFN-g, was sufficient to induce the interaction of iNOS with S100A8/A9 ( Figure 2E ). Because LDL ox induces Ca 2+ flux in leukocytes (van Tits et al., 2000) and both S100A8 and S100A9 are Ca 2+ -binding proteins (Hessian et al., 1993) , we investigated the role of Ca 2+ in complex assembly. In PBM ectopically expressing His-iNOS, LDL ox induced a 2.9-fold increase in cytosolic Ca 2+ , iNOS binding to S100A8/A9 and GAPDH S-nitrosylation ( Figure 2F ). Ca 2+ chelators BAPTA-AM or EGTA suppressed Ca 2+ induction by LDL ox and inhibited iNOS-S100A8/A9 complex assembly and GAPDH S-nitrosylation. Ca 2+ ionophores A23187 and ionomycin raised intracellular Ca 2+ to levels comparable to LDL ox -treated cells, but did not induce complex assembly, suggesting Ca 2+ is necessary but not sufficient for LDL ox -induced S-nitrosylation.
Transnitrosylase Activity of S100A9 Is Essential for GAPDH Cys 247 S-Nitrosylation S100A9 knockdown prevented inducible GAPDH S-nitrosylation, whereas S100A8 knockdown was ineffective, indicating S100A9 is essential for GAPDH S-nitrosylation ( Figure 3A) . We investigated the hypothesis that S100A9 not only mediates iNOS-GAPDH interaction, but also acts as a functional couple, transferring iNOS-derived NO to its target. LDL ox /IFN-g induced iNOS-dependent S-nitrosylation of S100A9 in PBM ( Figure 3B ). We considered the possibility that SNO-S100A9 acts as an S-nitrosylase, transferring the NO moiety to GAPDH. Purified S100A9 protein was subjected to in vitro S-nitrosylation by GSNO or GSH as negative control. After desalt, GSNO-modified S100A9 was incubated with purified GAPDH protein. GSNO led to S-nitrosylation of S100A9 that in turn induced GAPDH S-nitrosylation ( Figure 3C ). We determined the requirement for Cys 3 , the sole cysteine in human S100A9, for transnitrosylase activity. Endogenous S100A9 expression in PBM was silenced by 3 0 UTR-specific siRNA and replenished by cotransfection with myc-S100A9, wild-type or C3A mutant. S100A9 S-nitrosylation was abolished by S100A9 knockdown, as was GAPDH S-nitrosylation. Recombinant wild-type S100A9, but not C3A mutant, restored GAPDH S-nitrosylation, verifying the critical role of Cys 3 ( Figure 3D ). In addition, S100A9 knockdown rescued L13a from inducible degradation and restored GAIT-directed suppression of VEGF-A, establishing the link between S100A9 and translational control by the GAIT system. LDL ox /IFN-g induced S-nitrosylation of wildtype S100A9 and binding to both iNOS and S100A8 ( Figure 3E ). The C3A mutant interacted with S100A8 but failed to bind iNOS, suggesting Cys 3 S-nitrosylation is required for complex assembly, consistent with an important role of S-nitrosylation in protein interaction as described previously (Hess et al., 2005; Marozkina and Gaston, 2012) . for iNOS-S100A8/A9 complex assembly and activity. PBM that ectopically expressed His-iNOS were treated with LDL ox in the presence of calcium chelators 15 mM BAPTA-AM or 2 mM EGTA, or with calcium ionophores 5 mM A23187 or 1 mM ionomycin. Lysates were subject to IP and IB with indicated antibodies or Biot.-sw. analysis. Cytosolic calcium was determined with o-cresolphthalein at 575 nm, and normalized to total cytosolic protein (mean ± SEM, n = 5 experiments). See also Figure S1 and Table S1 .
Figure 2. S100A8/A9 Directs iNOS-GAPDH Interaction and GAPDH S-Nitrosylation

S100A8 Contributes to Site Selectivity of S-Nitrosylase Complex in GAPDH S-Nitrosylation
In contrast to S100A9, S100A8 depletion did not disrupt the iNOS-GAPDH interaction or prevent GAPDH S-nitrosylation ( Figures 2D and 3A) . We considered the possibility that S100A8 contributes to target specificity of S-nitrosylation. PBM were cotransfected with S100A8 siRNA and HA-GAPDH. Control cells treated with scrambled siRNA exhibited specific stimulus-inducible S-nitrosylation of GAPDH Cys 247 as shown by the total absence of modification of the C247S mutant (Figure 4A) . Remarkably, S100A8 knockdown permitted S-nitrosylation of C247S mutant indicating a loss of target specificity and suggests that S100A8 directs site selectivity of the iNOS-S100A8/A9 S-nitrosylase complex. S100A8 depletion permitted S-nitrosylation of GAPDH Cys 247 and Cys 152 , but not Cys 156 ( Figure 4B ). To elucidate the mechanism of S100A8-directed site-selection, the interaction of S100A8 and GAPDH was probed by His-tag pull-down. Purified GAPDH specifically bound recombinant human S100A8, but not EPRS WHEP-R1 control protein (Jia et al., 2008) (Figure 4C ). The GAPDH region that interacts with S100A8 was probed using the FeBABE (Fe(III) (s)-1-(pbromoacetamidobenzyl) EDTA) ''artificial protease'' method. The sole cysteine in S100A8, Cys 42 , was mutated to serine, and cysteine residues were introduced into S100A8 at ten amino acid intervals for covalent labeling with FeBABE. The site of interaction between HA-GAPDH and FeBABE-labeled S100A8 was detected by FeBABE-directed, hydroxyl radicalmediated cleavage mapping. Wild-type S100A8 and three mutants (I22C/C42S, D32C/C42S, and D52C/C42S) caused marked cleavage of GAPDH in helices a1 and a3 ( Figure 4D ). Importantly, GAPDH Cys 247 is located near the termini of both helices, suggesting S100A8 may contribute to specific GAPDH S-nitrosylation by proximity to the target cysteine ( Figure 4E ), possibly by altering the nearby structure. We applied Fö rster resonance energy transfer (FRET) to probe the S100A8-inducible conformational shift. GAPDH Cys 156 was mutated to Ser to generate a FRET donor-acceptor pair of Cys 152 and Cys 247 for dye labeling. GAPDH C156S was labeled with mixed thiolreactive dyes, Alexa 546-and 647-C5-maleimide. The apparent mean interfluor distance for GAPDH by itself was calculated to be 51.6 Å and increased to 58.0 Å by addition of S100A8 ( Figure S2 ), indicative of a substantial conformational shift, consistent with S-nitrosylation of tetrameric GAPDH as the X-ray structure (Ismail and Park, 2005) indicates the distance between the Cys-Cys pair in the monomer is 21 Å , whereas the maximum distance in the tetramer is 64.8 Å (Ismail and Park, 2005) .
iNOS-S100A8/A9 Directs Selective S-Nitrosylation of Multiple Targets We applied a global, proteomic approach to assess whether iNOS-S100A8/A9 nitrosylates other proteins. S100A9-depleted or untreated human PBM were incubated with LDL ox /IFN-g for 24 hr, and S-nitrosylated proteins in lysates were subjected to biotin-switch labeling and streptavidin-agarose pulldown. Following electrophoresis and Coomassie blue stain, bands identified in untreated, but not in S100A9-depleted cells, were selected for LC-MS analysis, and an ensemble of 95 SNO-protein candidates, including GAPDH and S100A9, were identified (Table S2) . LDL ox /IFN-g-inducible S-nitrosylation was determined for candidates having only one or two cysteines, thereby facilitating detailed analysis. Five of the nine candidates, annexin V, ezrin, HSPA5, moesin, and vimentin, exhibited robust, stimulus-inducible S-nitrosylation ( Figure 5A, left) . 1400W inhibited S-nitrosylation of all five candidates, indicating the requirement for iNOS. Four candidates were not S-nitrosylated indicating either false-positive LC-MS results, or possibly coprecipitation with S-nitrosylated interacting partners ( Figure 5A, right) . S100A9-depletion suppressed S-nitrosylation of annexin V, ezrin, moesin, and vimentin ( Figure 5B) S-nitrosylation was not affected by S100A9 depletion indicative of modification by an S100A9-independent S-nitrosylase. The possibility that a specific motif directs modification by iNOS-S100A8/A9 was explored by sequence alignment. 21 amino acids surrounding all seven cysteine residues in five validated target SNO-proteins (ezrin and moesin each contain two cysteines) were aligned. A conserved I/L-X-C-X 2 -D/E sequence is present at Cys 247 in GAPDH, in the two validated SNO-proteins containing a single cysteine, and in one of two cysteines in the other two validated proteins, but not in the nonvalidated proteins or at Cys 152 or Cys 156 in GAPDH ( Figure 5C ).
S-Nitrosylation Motif Directs Selective Target Recognition by iNOS-S100A8/A9
The function of the putative sequence motif was tested in GAPDH. , or both, in the consensus motif markedly abrogated LDL ox /IFN-ginducible S-nitrosylation of GAPDH at Cys 247 ( Figure 6A , top).
GSNO induced S-nitrosylation of wild-type and all mutant GAPDH isoforms equally showing a complete absence of target-specific S-nitrosylation by GSNO ( Figure 6A, bottom) .
To characterize the role of S100A8 in motif recognition, S-nitrosylation of motif mutants was assessed in S100A8-deficent cells. Unexpectedly, S100A8 depletion restored inducible S-nitrosylation of Cys 247 in the Leu 245 mutant, but not in the Glu 250 or double mutant, suggesting Leu 245 is necessary for motif recognition by S100A8 and Glu 250 is recognized by iNOS/S100A9 ( Figure 6B ). The GAPDH crystal structure indicates surfaceaccessibility of the three motif residues ( Figure 6C ).
To explore motif universality, the SNO-site of human moesin was investigated. Cys 117 and Cys 284 were individually mutated to Ser. LDL ox /IFN-g was unable to induce S-nitrosylation of C117S moesin indicating Cys 117 is the sole S-nitrosylation site ( Figures 6D and 6E, left) . In contrast to the loss of target specificity observed for GAPDH, depletion of S100A8 did not alter S-nitrosylation site selection in moesin, suggesting a possible steric constraint prevents transfer of the NO moiety ( Figures  6E, left, and 6F ). Cys 117 is within a predicted S-nitrosylation motif with Ile 115 and Glu 120 . As expected, LDL ox /IFN-g induced S-nitrosylation of wild-type moesin and the C284S mutant, but not motif-negative mutants containing I115M or E120M, or both ( Figure 6E , right, and 6G). S100A8 depletion restored S-nitrosylation of Ile 115 mutant, however, the Glu 120 mutation still blocked S-nitrosylation of moesin ( Figure 6H ). Consistent with GAPDH motif recognition, this result suggests a general rule in which the I/L residue is recognized by S100A8 and D/E is critical for S-nitrosylation by iNOS/S100A9 ( Figure 7A ). Together these experiments show that both the upstream and downstream components of the I/L-X-C-X 2 -D/E motif are required for LDL ox / IFN-g induced S-nitrosylation. Figure S2 .
To determine whether the motif is sufficient for S-nitrosylation, a gain-of-function approach was explored using moesin as target. We observed that the Cys 117 -containing motif is surface accessible and near the terminus of an a helix. As a target we selected a nearby surface accessible site near the terminus of a nearby a helix (H 161 -X-L 163 -X 2 -D 166 ) ( Figure 6E , right). -X 2 -E 166 , which conforms to the consensus S-nitrosylation motif. Moesin with a Cys residue inserted by an L163C mutation failed to be S-nitrosylated by LDL ox /IFN-g treatment ( Figure 6I ). However, the H161I/L163C double mutant was efficiently S-nitrosylated. Likewise, a H161I/L163C/D166E triple mutant was modified revealing a similar effectiveness of Asp and Glu.
DISCUSSION
S-nitrosylation has emerged as a dominant regulatory mechanism in NO-associated signal transduction and cell function (Gould et al., 2013; Smith and Marletta, 2012) . More than 3,000 S-nitrosocysteine sites have been identified by proteomic (B) S100A9-dependent S-nitrosylation of candidates. PBM were transfected with S100A9 (or scrambled) siRNA, and then treated with LDL ox / IFN-g. S-nitrosylation of iNOS-dependent candidates was determined by Biot.-sw. Protein expression was determined IB with antibodies indicated. (C) Identification of a putative S-nitrosylation consensus sequence in iNOS-S100A8/A9-S-nitrosylated proteins. Sequences ten amino acids upstream and downstream from every cysteine in five validated SNO-proteins and 12 sites in six proteins found to be not S-nitrosylated were aligned by Clustal X. Residues conforming to the consensus motif are boxed. See also Table S2. analysis of in vitro and in vivo S-nitrosylated proteins (Chen et al., 2010) . Despite the extreme diversity, the apparent fidelity and site-selective nature of the modification suggests precise regulation of the S-nitrosylation process (Seth and Stamler, 2011) . Using biochemical and genetic approaches, we have identified a stimulus-activated S-nitrosylase complex that directs motif-dependent protein S-nitrosylation in human myeloid cells (Figure 7) . IFN-g and LDL ox synergistically induce iNOS expression and initiate the assembly of a S-nitrosylase complex consisting of iNOS and S100A8/A9. LDL ox -inducible interaction of iNOS to S100A8 and S100A9, both calcium-binding proteins, is accompanied by induction of intracellular Ca 2+ , which may be mediated by the CD36 receptor and the Lyn/ Fyn-Vav signaling pathway (Rahaman et al., 2011) . Although S100A8 S-nitrosylated in vitro by GSNO can slowly transfer the NO group to hemoglobin (Lim et al., 2008b) , the function of intracellular S100A8/A9 in S-nitrosylation has not been investigated. In our studies, we show that S100A9 acts both as an adaptor linking iNOS to its target via protein-protein interaction and as a transnitrosylase that transfers the NO moiety from iNOS to its target, via its own S-nitrosylated Cys 3 . S100A8 interacts with the target and dictates site-specificity of the S-nitrosylase complex by motif recognition. S100A8 binding induces a conformational change in the target protein and restricts transfer of NO from S100A9 to the motif-associated cysteine.
All three NOS isoforms act as NO donors for target-selective S-nitrosylation in vivo (Seth and Stamler, 2011) . Importantly, individual NOS isoforms can direct selective S-nitrosylation of distinct cysteine residues in the same protein. In one well-studied example, iNOS induces GAPDH S-nitrosylation at either Cys 152 (Hara et al., 2005) or Cys 247 (Figure 1 ) in distinct cell types and in response to distinct stimuli, most clearly illustrating both high-level specificity as well as the utilization of multiple mechanisms. The recognition of a multitude of targets by just three NOS isoforms distinguishes S-nitrosylation from phosphorylation, a site-specific posttranslational modification mediated by $950 human kinases (Buzko and Shokat, 2002) . Multiple adaptor proteins might contribute to the specificity problem of substrate recognition by NOS isoforms. Supporting this mechanism, PSD-95 (Lipton et al., 2002) and CAPON (Fang et al., 2000) act as scaffolds that direct nNOS binding to its S-nitrosylation targets. This mechanism is analogous to the polyubiquitination system in which one of $520 E3 ubiquitin ligases act as adaptors to direct binding of the catalytic E2 ubiquitin-conjugating enzymes that transfer ubiquitin to the target lysine residue (Li et al., 2008) . The adaptor mechanism in site-selective S-nitrosylation is supported by our finding that S100A8/A9 directs the binding of iNOS to GAPDH. However, S100A8/A9 also exhibits transnitrosylase activity, transferring the NO group from the iNOS donor to GAPDH, as well as to four other validated targets . PBM were transfected with HA-GAPDH (WT and mutant). Cells were then incubated with LDL ox /IFN-g (top two panels) or 1 mM GSNO (lower two panels). Cell lysates were subjected to IP and IB as indicated; protein S-nitrosylation was determined by Biot.-sw. (B) S100A8 directs motif recognition in GAPDH Snitrosylation. PBM were transfected with HA-GAPDH (WT or C247S), or cotransfected with S100A8 siRNA and HA-GAPDH mutant. Cell lysates were subjected to IP and IB with antibodies indicated. Protein S-nitrosylation was determined by Biot.-sw. and $90 other candidates. Interestingly, nNOS S-nitrosylates PSD-95 at Cys 3 and Cys 5 (Ho et al., 2011) , but their role in NMDAR S-nitrosylation, and the possible function of PSD-95 as an nNOS-associated S-nitrosylase, has not been determined.
Despite considerable effort, a specific consensus sequence or motif that directs S-nitrosylation globally or in an ensemble of proteins has not been identified (Doulias et al., 2010; Marino and Gladyshev, 2010; Seth and Stamler, 2011) . The difficulty of deconvolving the signal of a dominant motif from a multitude of sequences targeted by diverse S-nitrosylases and adaptors has rendered this problem nearly insoluble. The complexity of the problem is multiplied further by the diminished specificity of S-nitrosylation by chemical NO donors that that can generate up to 1000 SNO-proteins. We took advantage of an analysis of a select family of SNO-proteins, revealed by proteomic analysis and experimentally validated to be specifically S-nitrosylated by the iNOS-S100A8/A9 complex. A consensus I/L-X-C-X 2 -D/E motif was observed in five S-nitrosylated proteins. Disruption of conserved residues I/L and/or D/E in the motif blocked S-nitrosylation in both proteins tested at the predicted sites, A B Figure 7 . Schematic of iNOS-S100A8/A9-Directed, Site-Selective S-Nitrosylation (A) S100A8 and S100A9 coordinately direct targetselective S-nitrosylation by recognition of [I/L]-X-C-X 2 -[D/E] motif. NO moiety is transferred from iNOS to S100A9 Cys 3 and then to cysteine in the target motif (left); or to other accessible cysteine residues in the absence of S100A8 (right).
(B) LDL ox /IFN-g induces iNOS expression, iNOS-S100A8/A9 complex assembly, and target-selective S-nitrosylation, which causes GAIT pathway dysregulation, and is likely to influence other myeloid cell functions.
Cys 247 of GAPDH and Cys 117 of moesin.
Mutation of amino acids in the consensus motif did not inhibit S-nitrosylation of GAPDH Cys 247 by GSNO, consistent with previous reports of lack of specificity of GAPDH S-nitrosylation by GSNO (Paige et al., 2008; Wu et al., 2011) . Exogenous, nonenzymatic donors induce high, nonphysiological intracellular NO concentrations, that can direct nonselective S-nitrosylation of free, surface-accessible cysteine residues. The dissimilar, sitespecific S-nitrosylation of GAPDH at Cys 152 by apoptotic agonists suggests the activity of a distinct S-nitrosylase and cognate motif (Hara et al., 2005) . Certainly, the I/L-X-C-X 2 -D/E motif is not required for all, or even most site-selective protein nitrosylations, as exemplified by apoptosis-driven stimulation of Snitrosylation of GAPDH Cys
152
, which is not located within the consensus motif. More interestingly, HSPA5 is subject to LDL ox /IFN-g-stimulated S-nitrosylation but neither of the two cysteine residues are contained within the consensus motif, and the modification requires iNOS, but not S100A8/A9. This result indicates that a single stimulatory condition, i.e., LDL ox / IFN-g, can activate site-selective S-nitrosylation by multiple mechanisms.
Several structural factors have been suggested to contribute to protein S-nitrosylation, including acid-base sequences in residues within 6-8 Å (Marino and Gladyshev, 2010) , nearby hydrophobic residues (Seth and Stamler, 2011) , high nucleophilicity (Hess et al., 2005) , helical structure, and solvent accessibility (Doulias et al., 2010) . Interestingly, the I/L-X-C-X 2 -D/E motif described here exhibits most, if not all, of these characteristics. The Cys residue is surrounded by a nearby acidic residue, D/E, and a hydrophobic residue, I/L, which can increase cysteine nucleophilicity. In addition, according to X-ray crystal structures, the S-nitrosylated cysteine in each of the validated SNO-proteins is solvent-accessible and located within or adjacent to a-helical domains (Edwards and Keep, 2001; Huber et al., 1992; Nicolet et al., 2010; Smith et al., 2003) . The I/L-X-C-X 2 -D/E motif is present in 19 additional candidate SNO-proteins revealed by our proteomic analysis (Table S2) , suggesting a wide-ranging role in S-nitrosylation. Ontologic analysis of motif-bearing candidates suggests linkage to cytoskeleton organization, cell movement, catabolic processes, inflammation, and protein localization (Huang et al., 2009 ). Analysis of a SNO-protein database that includes 810 SNO-peptides in 445 human proteins (Lee et al., 2012) revealed only 15 peptides in 15 proteins contain the I/L-X-C-X 2 -D/E motif. This result is consistent with a relatively high specificity and low occurrence of nitrosylation by the iNOS-S100A8/A9 complex compared to chemical NO donors. S100A9, in the absence of S100A8, has the potential to increase the target range by recognition of a less stringent CX 2 D/E motif ( Figures 6B and 6H) . However, this situation may not be physiologically relevant because S100A9 by itself is unstable (Riva et al., 2013) . Likewise, rapid turnover of S100A8 in S100A9 null mice suggests heterodimer formation is important to maintain expression and function of the complex (Hobbs et al., 2003) . S100A8 and S100A9 are constitutively expressed in myeloid cells and predominantly found as a heterodimeric complex in vivo. S100A8/A9 comprises $1% of total protein in monocytes attesting to its potential pathophysiological significance (Edgeworth et al., 1991) . S100A8/A9 is generally considered to be a proinflammatory agent, however, the specific cellular functions of S100A8/A9 are incompletely understood (Goyette and Geczy, 2011; Roth et al., 2003) . Release of S100A8/A9 by activated neutrophils, monocytes, and platelets has led to a primary focus on the extracellular functions. Its plasma level in humans is associated with increased risk for CVD Nagareddy et al., 2013) , possibly by contributing to both innate and adaptive immune responses. The complex is particularly abundant in inflammatory sites, including atherosclerotic lesions of mice and humans, and its level correlates with characteristics or rupture-prone plaques (Croce et al., 2009; Ionita et al., 2009; McCormick et al., 2005) . Genetic deletion of S100A9 decreases atherosclerotic lesion formation in apoE À/À mice (Croce et al., 2009 ). Possibly, S100A9 depletion restores GAIT system activity by blocking GAPDH Cys 247 S-nitrosylation and L13a degradation thereby suppressing expression of inflammation-related proteins. However, the stimulatory role of S100A8/A9 in atherosclerotic lesion formation has not been uniformly observed in other mouse models (Averill et al., 2011; Croce et al., 2009 ). Interestingly, both S100A9 and iNOS are enriched in macrophagerich regions in the Alzheimer's disease (AD) brain, and depletion of either provides significant clinical benefits in animal models of AD (Ha et al., 2010; Nathan et al., 2005) . Recent studies of differential protein S-nitrosylation revealed 45 AD-associated SNO-proteins in humans and 33 in mouse models of AD (Zahid et al., 2014; Zarę ba-Kozio1 et al., 2014) . Interestingly, six human and six mouse AD-associated SNO-proteins contain the I/L-X-C-X 2 -D/E motif. The intracellular activities of S100A8/A9, and particularly their potential contributions to cellular inflammation remain largely unexplored. S100A8/A9 may contribute to myeloid cell inflammation via S-nitrosylation of inflammatory mediators in addition to GAPDH. Several candidate or validated SNO-proteins revealed by our analysis are linked to myeloid cell inflammatory processes, such as CAP1 (Lee et al., 2014) and SAMHD1 (Laguette et al., 2011) . Moreover, S100A8/A9 has been implicated in additional intracellular functions, including cytoskeleton organization (Vogl et al., 2004) and gene regulation (Schonthaler et al., 2013) . Our discovery of an inflammatory stimulus-dependent S-nitrosylase complex, and its recognition motif, opens a new avenue of thought in deciphering the role of S-nitrosylation in inflammation, the specific participants, and the underlying molecular mechanisms.
EXPERIMENTAL PROCEDURES
For additional details, see Extended Experimental Procedures.
Primary Cells
Primary human PBM were isolated from healthy donors under a Cleveland Clinic Institutional Review Board-approved protocol that adhered to American Association of Blood Bank guidelines (Jia et al., 2012) . Bone marrow-derived macrophages (BMDM) were harvested and cultured from femurs of wildtype or iNOS À/À mice in C57BL/6J background (Jackson Laboratory, Bar
Harbor) under a protocol approved by the Cleveland Clinic Institutional Animal Care and Use Committee. More details are described in the Extended Experimental Procedures.
Biotin-Switch and Protein S-Nitrosylation Assay
Cell lysates (1 mg protein) were subjected to biotin-switch labeling as described (Jia et al., 2012) by using S-nitrosylated Protein Detection Kit (Cayman). In vitro transnitrosylase activity of S100A9 was determined as described (Kornberg et al., 2010) . Purified S100A9 protein was incubated with 100 mM GSH control or GSNO in the dark for 30 min at room temperature. After desalting, S100A9 was incubated with purified GAPDH for additional 30 min and then subjected to biotin-switch analysis.
S100A8-GAPDH Interaction Experiments
S100A8-GAPDH interaction was determined in vitro using His Protein Interaction Pull-down Kit (Pierce). His-S100A8 and His-WHEP-R1 were expressed in Escherichia coli and purified. His-protein (1 nmol) was immobilized on cobalt agarose resin and then incubated with 2-fold molar excess of purified GAPDH for 1 hr. Eluted protein was subjected to electrophoresis and immunoblot analysis. The FeBABE (Fe(III) (s)-1-(p-bromoacetamidobenzyl) EDTA) ''artificial protease'' method was used for mapping S100A8 interacting sites on GAPDH. The sole cysteine in S100A8, Cys 42 , was mutated to serine, and additional cysteine was introduced into S100A8 at ten amino acid intervals for covalent labeling with FeBABE and the proteins expressed in E. coli and purified. S100A8 (10 nmol) was labeled using FeBABE Protein Interaction Mapping Kit (Pierce) according to manufacture's protocol. HA-GAPDH (50 pmol) was mixed with equimolar FeBABE-labeled S100A8 for 1 hr and subjected to FeBABE-directed, hydroxyl radical-mediated cleavage mapping. Samples were immediately subjected to electrophoresis and IB with anti-HA tag antibody. Cleavage sites were determined within eight to ten residues by determining the molecular weight of GAPDH fragments based on standard protein markers as described (Chen and Hahn, 2003) .
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, two figures, and two tables and can be found with this article online at http://dx. doi.org/10.1016/j.cell.2014.09.032.
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